Can a single extra insulin dose speed up blood sugar control?

NCT ID NCT07747402

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests different ways to start once-weekly insulin icodec in adults with type 2 diabetes who haven't used insulin recently. Participants are randomly assigned to one of three starting-dose methods: a fixed dose, a dose based on their fasting blood sugar, or a dose based on body weight. Half also receive an extra half-dose on day 4 if their blood sugar is still high. The goal is to see which approach helps more people reach their fasting blood sugar target within the first week, while keeping safety in mind.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Insulin icodec, a once-weekly injectable insulin
What this could lead to
If successful, this could identify the safest and most effective way to start once-weekly insulin, helping more people with type 2 diabetes reach their blood sugar goals within the first week of treatment.
What could go wrong
This is a phase 4 trial, so the drug is already approved, but the best starting dose strategy is still unclear. The extra day-4 dose might increase the risk of low blood sugar, and results may not apply to everyone with type 2 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xi'an International Medical Center Hospital

    Xi'an, Shaanxi, 710100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.